Frank Karbe Myovant Sciences Ltd. (MYOV) insider trading activity

Frank Karbe is Principal Fin'l & Accounting of Myovant Sciences Ltd.. Currently has a direct ownership of 212,296 shares of MYOV, which is worth approximately $0. The most recent transaction as insider was on Jul 07, 2021, when has been sold 3,232 shares (Common Shares) at a price of $21.75 per share, resulting in proceeds of $70,296. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 212K

0% 3M change

0% 12M change

Total Value Held $0

FRANK KARBE Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 07 2021	SELL Open market or private sale	$70,296 $21.75 p/Share	3,232 Reduced 1.5%	212,296 Common Shares
Apr 15 2021	BUY Grant, award, or other acquisition	-	63,138 Added 22.66%	215,528 Common Shares
Apr 06 2021	SELL Open market or private sale	$206,420 $18.63 p/Share	11,080 Reduced 6.78%	152,390 Common Shares
Feb 16 2021	SELL Open market or private sale	$16,050 $21.4 p/Share	750 Reduced 0.46%	163,470 Common Shares
Feb 16 2021	BUY Exercise of conversion of derivative security	$3,833 $5.11 p/Share	750 Added 0.45%	164,220 Common Shares
Jan 28 2021	SELL Open market or private sale	$7,200 $24.0 p/Share	300 Reduced 0.18%	163,470 Common Shares
Jan 28 2021	BUY Exercise of conversion of derivative security	$1,533 $5.11 p/Share	300 Added 0.18%	163,770 Common Shares

Jan 15 2021	SELL Open market or private sale	$16,125 $21.5 p/Share	750 Reduced 0.46%	163,470 Common Shares
Jan 15 2021	BUY Exercise of conversion of derivative security	$3,833 $5.11 p/Share	750 Added 0.45%	164,220 Common Shares
Dec 28 2020	SELL Open market or private sale	$354,000 $30.0 p/Share	11,800 Reduced 6.73%	163,470 Common Shares
Dec 28 2020	BUY Exercise of conversion of derivative security	$60,298 $5.11 p/Share	11,800 Added 6.31%	175,270 Common Shares
Dec 15 2020	SELL Open market or private sale	$8,979 $23.63 p/Share	380 Reduced 0.23%	164,140 Common Shares
Dec 15 2020	SELL Open market or private sale	$16,382 $24.45 p/Share	670 Reduced 0.41%	163,470 Common Stock
Dec 15 2020	BUY Exercise of conversion of derivative security	$5,366 $5.11 p/Share	1,050 Added 0.63%	164,520 Common Shares
Nov 30 2020	SELL Open market or private sale	$36,000 $24.0 p/Share	1,500 Reduced 0.91%	163,470 Common Shares
Nov 30 2020	BUY Exercise of conversion of derivative security	$7,665 $5.11 p/Share	1,500 Added 0.9%	164,970 Common Shares
Nov 17 2020	SELL Open market or private sale	$15,000 $20.0 p/Share	750 Reduced 0.46%	163,470 Common Shares
Nov 17 2020	BUY Exercise of conversion of derivative security	$3,833 $5.11 p/Share	750 Added 0.45%	164,220 Common Shares
Nov 13 2020	SELL Open market or private sale	$15,000 $20.0 p/Share	750 Reduced 0.46%	163,470 Common Shares
Nov 13 2020	BUY Exercise of conversion of derivative security	$3,833 $5.11 p/Share	750 Added 0.45%	164,220 Common Shares

Also insider at

PHAT

Phathom Pharmaceuticals, Inc. Healthcare

BTTX

Better Therapeutics, Inc. Healthcare

Chief Executive Officer

Frank Karbe

Principal Fin'l & Accounting

San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MYOV shares.

Notify only if

Value

Insider Trading

Get notified when an Myovant Sciences Ltd. insider buys or sells MYOV shares.

Notify only if

Operation

Value

Type

News

Receive news related to Myovant Sciences Ltd.

Track Activities on MYOV

Account